To include your compound in the COVID-19 Resource Center, submit it here.

Genentech, OSI, Roche deal

OSIP licensed its OSI-774 oral EGF receptor inhibitor to ROCZ and DNA.

Read the full 128 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE